TLSI — TriSalus Life Sciences, Inc.

TriSalus Life Sciences Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q1 revenue was $8.9 million, a slight decrease from $9.2 million in the prior year, attributed to disruptions from an expanded sales organization.
• Gross Margin: Improved to 86% from 84% year-over-year, driven by lower average unit costs.
• Operating Loss: Net operating loss increased to $8.4 million from $7.3 million, reflecting lower revenue and increased sales and marketing investments.
• Adjusted EBITDA Loss: Approximately $5.8 million, compared to $5.5 million in Q1 2025.
• Cash Position: As of March 31, 2026, cash and cash equivalents totaled $56.6 million.

2. Strategic Updates and Business Highlights

• Commercial Organization Expansion: TriSalus has significantly expanded its commercial team to enhance physician engagement and cover new applications, with a focus on the liver embolization market.
• New Leadership: Chris Sowd was appointed as Senior VP of Sales and Commercial Operations, bringing extensive experience in diagnostics and life sciences.
• Real-World Evidence Study: A landmark study on the pressure-enabled drug delivery (PEDD) technology was published, demonstrating improved clinical outcomes and cost avoidance of approximately $7,700 per patient.
• New Applications: Progress in new applications such as uterine artery, thyroid artery, and genicular artery embolization, with promising preliminary results from ongoing studies.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year 2026 revenue is revised to a range of $54 million to $57 million, reflecting lower Q1 revenues and delays in FDA clearance for the TriNav Advance device.
• Sales Productivity: Management expects sales productivity to improve throughout the year as the new sales team ramps up.
• Clinical Data Pipeline: Continued generation of clinical evidence with multiple ongoing studies, expected to drive adoption and revenue growth.

4. Bad News, Challenges, or Points of Concern

• Sales Disruption: Approximately 40% of sales territories experienced disruptions due to the reorganization, impacting Q1 performance.
• FDA Clearance Delay: The FDA review for TriNav Advance is running five months past the expected timeline, affecting anticipated revenue in the second half of the year.
• Increased Operating Loss: The increase in operating loss reflects both lower revenue and higher investments in sales and marketing, raising concerns about short-term profitability.

5. Notable Q&A Insights

• Sales Organization Size: The sales organization has been more than doubled, with a focus on attracting high-caliber talent from larger companies.
• Ramp-Up Period: New sales representatives typically require a 6- to 9-month ramp-up period, but some are already showing strong early performance.
• Impact of PEDD Data: The real-world data on PEDD is expected to resonate with both interventional radiologists and oncologists, potentially influencing treatment standards and adoption rates.
• Confidence in Growth: Management expressed confidence in achieving revenue guidance and emphasized the long-term growth potential across various applications.

Overall, while TriSalus faces short-term challenges related to sales disruptions and FDA delays, the company remains optimistic about its strategic initiatives and the long-term value of its PEDD technology.